Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Protocol No
NRG-GI008-CIRCULATE-NA
Staff Member
James Thomas
Phase
II/III
Summary

The purpose of this study is to find out if using ctDNA testing results can be used to determine if the usual approach or mFOLFIRINOX should be used to prevent colon cancer from returning in patients that are ctDNA positive and if the usual approach compared to ctDNA testing every 3 months in ctDNA negative patients should be used to prevent colon cancer from returning. The use of chemotherapy has side effects, which are described in the risks section below.
Objective
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Study Sites
Froedtert West Bend Hospital Drexel Town Center Froedtert Hospital Froedtert Menomonee Falls Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer, Colorectal, Gastrointestinal Cancers
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT05174169